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Abstract 
Purpose: Pomegranate fruit, Punica granatum L. (Punicaceae) and its constituents 
have been shown to inhibit inflammation. In this study we aimed to assess the 
effects of freeze-dried pomegranate (PWE) on PGE2 production in IL-1 stimulated 
SK-N-SH cells. 
Methods: An enzyme immuno assay (EIA) was used to measure prostaglandin E2 
(PGE2) production from supernatants of IL-1 stimulated SK-N-SH cells. Expression 
of COX-2, phospho-IκB and phospho-IKK proteins were evaluated, while NF-κB 
reporter gene assay was carried out in TNF-stimulated HEK293 cells to determine 
the effect of PWE on NF-κB transactivation. Levels of BACE-1 and A in SK-N-SH 
cells stimulated with IL-1 were measured with an in cell ELISA. 
Results: PWE (25-200 µg/ml) dose dependently reduced COX-2 dependent PGE2 
production in SK-N-SH cells stimulated with IL-1. Phosphorylation of IκB and IKK 
were significantly (p<0.001) inhibited by PWE (50- 200 µg/ml). Our studies also show 
that PWE (50-200 µg/ml) significantly (p<0.01) inhibited NF-κB transactivation in 
TNF-stimulated HEK293 cells. Furthermore PWE inhibited BACE-1 and A 
expression in SK-N-SH cells treated with IL-1. 
Conclusions: Taken together, our study demonstrates that pomegranate inhibits 
inflammation, as well as amyloidogenesis in IL-1-stimulated SK-N-SH cells. We 
propose that pomegranate is a potential nutritional strategy in slowing the 
progression of neurodegenerative disorders like Alzheimer’s disease. 
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Introduction 1 
Alzheimer’s disease (AD) is still the most common cause of dementia accounting for 2 
50% to 75% of all cases [1], especially in the elderly [2]. As the population of the 3 
European continent continues to age, it is predicted that AD will continue to be a 4 
major public health problem. Consequently, there is need to identify and develop 5 
therapeutic strategies aimed at delaying progression of AD. 6 
Neurodegeneration in AD is linked to the accumulation of senile plaques which 7 
consist of small peptides, known as amyloid- (A), and intracellular neurofibrillary 8 
tangles, consisting of aggregates of hyperphosphorylated tau protein [3]. 9 
Neuroinflammation is a process which principally involves activation of astrocytes 10 
and microglia by inflammatory mediators in AD [4, 5]. However, in spite of the widely-11 
reported roles of microglia and astrocytes in neuroinflammation, it has been 12 
suggested that PGE2 produced in neurons may contribute to the self-propagating 13 
processes involved in AD. For instance, Hoshino et al. showed that PGE2 stimulates 14 
the production of A in cultured human neuroblastoma (SH-SY-5Y) cells [6]. Also, 15 
reports have demonstrated elevated levels of PGE2 and COX-2 in the brains of AD 16 
patients [7, 8]. Inhibition of PGE2 production and COX-2 expression therefore 17 
provides a critical target for reducing the contributions of neurons to the self-18 
perpetuating cycle of neuroinflammation. 19 
The production of COX-2 and other inflammatory factors is regulated by the 20 
transcription factor, nuclear factor-kappa B (NF-κB), which has been shown to be 21 
widely expressed in the brain. Evidences have been put forward that NF-κB 22 
signalling pathways may be activated in AD brains [9]. These have been supported 23 
by reports demonstrating that A peptides could activate NF-κB in neurons [10]. 24 
NFκB pathway therefore provides an important target in the understanding of 25 
mechanisms involved in modulating inflammation in the neurons. 26 
Accumulation of extracellular A plaques in neurons is one of the important 27 
pathological hallmarks in AD. Also, the beta-site amyloid precursor protein cleaving 28 
enzyme1 (BACE-1) play a key role in the processing of A and its aggregation 29 
through catalysing amyloid precursor protein (APP) [11]. Various studies have 30 
demonstrated that the transcription of BACE-1 is controlled by NF-κB, and thus A 31 
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production in neurons [12, 13 14, 15]. In this regard targeting BACE-1 and A 32 
production could be a potential strategy in slowing down the progression of AD. 33 
Pomegranate fruit (Punica granatum L.) is widely consumed for its broad spectrum of 34 
nutritional and health benefits. Pomegranate contains polyphenols and tannins, 35 
which have been shown to be responsible for most of its nutritional benefits. Extracts 36 
and bioactive constituents of pomegranate fruit have been shown to suppress 37 
inflammation. Components such as punicalagin and punicalin have been shown to 38 
reduce nitric oxide and PGE2 production in intestinal cells [16, 17]. In vitro and in vivo 39 
studies showed that pomegranate produced significant reduction in egg albumin-40 
induced hind paw inflammation following intraperitoneal and intracerebroventricular 41 
administrations in rats, reduction in carrageenan-induced paw oedema, and NO 42 
production and iNOS expression in RAW 264.7 cells [18, 19]. Recently, we showed 43 
that one of the bioactive components of pomegranate, punicalagin inhibited 44 
neuroinflammation in LPS-activated microglia [20]. In spite of accumulating evidence 45 
showing that inflammation in neurons contribute to the pathology in AD, it is not 46 
currently known if pomegranate or its constituents produce any direct effect on these 47 
cells. In this study, we have evaluated the activity of freeze-dried pomegranate juice 48 
on PGE2 production in IL-1-stimulated SK-N-SH cells. In light of the importance of 49 
neuroinflammation to amyloidogenesis, we also investigated whether pomegranate 50 
could inhibit BACE-1 and A protein expression in IL-1-activated neuronal cells. 51 
Materials and methods 52 
Materials 53 
Pomegranate juice (POM Wonderful LLC, Los Angeles, CA) was freeze-dried to a 54 
solid sample (PWE) which was then reconstituted in sterile water and stored at -55 
20°C. Pomegranate juice used in this study was made from fruit skins, which has 56 
been standardised to ellagitannins, as punicalagins (80-85%) and free ellagic acid 57 
(1.3%) as determined by high-performance liquid chromatography [21]. 58 
Cell culture 59 
The human neuroblastoma (SK-N-SH) cells were obtained from the HPA Culture 60 
Collection (Salisbury, UK) and were grown in MEM-Eagle's medium (Life 61 
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Technologies, UK). Medium was supplemented with 10% foetal bovine serum 62 
(Sigma, UK), 2 mM L-glutamine, 1 mM sodium pyruvate, 40 units/ml 63 
penicillin/streptomycin (Sigma, UK). Confluent monolayers were passaged routinely 64 
by trypsinisation. Cultures were grown at 37°C in 5% CO2 until 80% confluence, and 65 
the medium was to serum free MEM the day before treatment. 66 
HEK293 cells were obtained from the HPA Culture Collection (Salisbury, UK) and 67 
were grown in MEM-Eagle's medium (Life Technologies, UK). Medium was 68 
supplemented with 10% foetal bovine serum (Sigma, UK), 2 mM L-glutamine, 1 mM 69 
sodium pyruvate, 40 units/ml penicillin/streptomycin (Sigma, UK). Confluent 70 
monolayers were passaged routinely by trypsinisation. Cultures were grown at 37°C 71 
in 5% CO2 until 80% confluence. 72 
PGE2 measurement 73 
Quantification of PGE2 accumulation was carried out in SK-N-SH cells by seeding in 74 
96-well plates (2 × 105/well), cultured for 48 h, and incubated with or without IL-1 75 
(10 U/ml) in the absence or presence of PWE (25-200 µg/ml) for 24 h. PGE2 76 
concentration was assessed in cell supernatants with a commercially available kit 77 
(Arbor Assays, Ann Arbor, MI, USA), followed by measurement at 450 nm with a 78 
microplate reader. Experiments were performed at least three times and in triplicate. 79 
Sandwich ELISA for COX-2, phospho-IκB and phospho-IKK 80 
Protein expressions of COX-2, phospho-IκB and phospho-IKK were determined 81 
using an ELISA for human COX-2, phospho-IκB and phospho-IKK. Cultured SK-82 
N-SH cells were stimulated with IL-1 (10 U/ml) in the presence or absence of PWE 83 
(25-200 µg/ml) for 24 h (COX-2), or 5 min (phospho-IκB and phospho-IKK). At the 84 
end of the experiments, cells were washed with phosphate-buffered saline (PBS) 85 
and lysed with 400 µl cell lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM 86 
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM -87 
glycerophosphate, 1 mM Na3VO4, 1 g/ml leupeptin) and incubated on ice for 5 min. 88 
The cells were then scraped and centrifuged at 13,500 rpm. Cell lysates were 89 
collected and measured for levels of COX-2, phospho-IκB and phospho-IKK, 90 
using a PathScan® sandwich ELISA kit (Cell Signalling Technology), according to the 91 
manufacturer’s instructions.  92 
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Transient transfection and luciferase reporter gene assay 93 
In order to determine the effect of PWE on the transactivation of NF-κB, a luciferase 94 
reporter gene assay was carried out. HEK293 cells were seeded out at a 95 
concentration of 4 × 105 cells/ml. Twenty-four hours later, cells were transfected with 96 
a Cignal® NF-κB Reporter (luc) (SABiosciences), using TransIT®-LT1 transfection 97 
reagent (Mirus Bio LLC) and incubated for a further 16 h at 37°C in 5% CO2. Twenty-98 
four hours later, transfected HEK293 cells were stimulated with TNF (1 ng/ml) in the 99 
presence or absence of PWE (25-200 µg/ml) for 6 h. NF-κB-mediated gene 100 
expression was measured with ONE-Glo luciferase assay kit (Promega, 101 
Southampton, UK) according to the manufacturer’s instructions. 102 
In Cell ELISA for BACE1 and A  103 
In Cell ELISA is used for quantitative protein analysis directly in adherent cell 104 
cultures, and was used to measure BACE-1 and A protein expression following 105 
stimulation of SK-N-SH cells with IL-1, as described earlier [22]. The protocol was 106 
based on the MaxDiscovery In Cell ELISA kit (Bio Scientific, Texas). SK-N-SH cells 107 
were seeded out in a 96-well plate (2.5 × 105 cells/ml). At 80% confluence, cells were 108 
pre-treated with PWE (25-200 µg/ml) 30 min before stimulation with IL-1 (10 U/ml) 109 
for 24 h. At the end of stimulation, cells were washed with 100 µl PBS, fixed and 110 
permeabilised. Primary antibodies (rabbit anti-BACE-1 or rabbit anti-A) were diluted 111 
1:100 and added to each sample well and incubated at room temperature for 1 h. 112 
This was followed by incubation with HRP-conjugated anti-rabbit IgG antibody at 113 
room temperature for 1 h. TMB solution was added, followed by stop solution and 114 
the plate read at 450 nm using a Tecan F50 microplate reader. GAPDH was used as 115 
internal control. 116 
Determination of cell viability 117 
Viability of SK-N-SH cells treated with IL-1 (10 U/ml) in the presence or absence of 118 
PWE (25-200 µg/ml) was measured by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-119 
diphenyltetrazolium bromide (MTT) assay. Cells were seeded in 96-well plates (2 × 120 
105 cells/ml) and incubated for 48 h. Thereafter, cells were pre-treated with PWE 121 
(25-200 µg/ml) prior to stimulation with IL-1 (10 U/ml). Twenty-four hours after 122 
stimulation, culture medium was replaced with MTT solution (5 mg/ml) and incubated 123 
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for 4 h at 37°C in 5% CO2. Thereafter 150 µl of MTT solution was replaced with 124 
DMSO and mixed thoroughly on a plate shaker and read at 540 nm. 125 
Cell viability was also measured using the Lactate dehydrogenase (LDH) assay [23]. 126 
LDH is a cytosolic enzyme that is an indicator of cellular toxicity. When the plasma 127 
membrane is damaged, LDH is released into cell culture media. Cells were seeded 128 
in 96-well plates (2 × 105 cells/ml) and incubated for 48 h. Thereafter, cells were pre-129 
treated with PWE (25-200 µg/ml) prior to stimulation with IL-1 (10 U/ml). Cells were 130 
then lysed and supernatants collected for LDH assay. LDH levels in supernatants 131 
were determined using the CytoTox 96® non-radioactive cytotoxicity assay kit 132 
(Promega, Southampton). 133 
Statistical analysis 134 
Values of all experiments were represented as mean ±SEM of at least 135 
3 experiments. Values were compared using t-test (two groups) or one-way ANOVA 136 
with post-hoc Student Newman–Keuls test (multiple comparisons). Levels of 137 
significance were set at *p < 0.05, **p<0.01, ***p<0.001. 138 
Results 139 
PWE reduced PGE2 production by inhibiting cyclooxygenase-2 (COX-2) protein 140 
expression in IL-1-activated SK-N-SH cells. 141 
In the presence of IL-1β (10 U/ml), there was a marked increase (***p<0.01) in PGE2 142 
production in supernatants of SK-N-SH cells, when compared to unstimulated cells. 143 
However, treatment with PWE (25-200 µg/ml) for 30 min prior to stimulation with IL-144 
1β resulted in significant reduction (***p<0.001) in PGE2 production, in comparison 145 
with IL-1β control (Fig. 1). PGE2 is synthesised through the enzymatic activity of 146 
COX-2. Consequently, we sought to determine whether the effect of PWE on PGE2 147 
was mediated through inhibition of the activities of this enzyme. Interestingly, 148 
experiments showed that PWE (25-200 µg/ml) produced significant reduction 149 
(***p<0.001) in COX-2 protein levels in IL-1-stimulated SK-N-SH cells (Fig. 2). 150 
PWE inhibited NF-κB dependent reporter gene expression in TNF activated 151 
HEK293 cells. 152 
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In order to determine the effect of PWE on the transactivation of NF-κB, a luciferase 153 
reporter gene assay was carried out. We observed that stimulation of transfected 154 
cells with TNF (1 ng/ml) resulted in activation of the NF-κB-driven luciferase 155 
expression (Fig. 3). Pre-incubation with PWE (25 g/ml) did not affect luciferase 156 
expression. However, pre-treatment with 50, 100 and 200 µg/ml of PWE resulted in 157 
significant (p<0.01) and concentration-dependent inhibition of NF-κB-driven 158 
luciferase expression, demonstrating that PWE suppresses NF-κB-dependent gene 159 
expression in general. 160 
PWE inhibited IL-1 dependent IκB and IKK phosphorylation in SK-N-SH cells. 161 
Based on our observation that PWE inhibited NF-κB-mediated gene expression in 162 
general, we sought to investigate its effect on IKK and IκB phosphorylation following 163 
stimulation with IL-1β (10 U/ml). Using a sandwich ELISA kit, we observed that IL-1β 164 
treatment resulted in phosphorylation of IKK and IκB in IL-1 treated cells, compared 165 
with unstimulated cells. These were significantly inhibited by pre-treatment with 50, 166 
100 and 200 µg/ml of PWE (Fig. 4 and 5). 167 
Pre-treatment of SK-N-SH cells with PWE resulted in inhibition of BACE-1 and 168 
A proteins 169 
Exposure of the cells to IL-1 resulted in a marked increase in both BACE-1 and A 170 
proteins (Fig. 6 and 7). However, pre-treatment with PWE (50,100 and 200 µg/ml) 171 
significantly reduced the levels of BACE-1 and A proteins. 172 
PWE did not affect the viability of SK-N-SH cells 173 
In order to show that PWE did not affect viability of SK-N-SH cells at concentrations 174 
used in this experiment, an MTT assay was performed. Results showed that 175 
treatment with PWE (25-200 µg/ml) did not have significant effect on the viability of 176 
the cells (Fig. 8a). LDH assay also showed that concentrations of PWE used for 177 
pharmacological investigations did not affect viability (Fig. 8b). These results suggest 178 
that the observed effects of PWE were not due to cytotoxicity as a result of 179 
decreased live cells. 180 
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Discussion 181 
Studies on the role of neuroinflammation in AD have focused mainly on the activity of 182 
the microglia. However, studies have shown that inflammation in neurons also 183 
contribute to the self-perpetuating processes leading to neuronal loss. For example, 184 
studies have shown that PGE2 is able to stimulate A production in SH-SY5Y cells 185 
[6]. Furthermore, IL-18 has been shown to increase BACE-1 expression in 186 
differentiated SH-SY5Y cells [24]. We therefore investigated whether pomegranate 187 
could affect IL-1-induced PGE2 production, as well as BACE-1 and A production in 188 
SK-N-SH cells. 189 
Studies have shown that elevated levels of COX-2 and its metabolic product PGE2 190 
was observed in AD brains, while COX-2 inhibitors markedly reduce the risk of AD 191 
[25]. Recent in vivo studies also show that long term treatment of APP transgenic 192 
mice with NSAIDs significantly diminished inflammatory factors and its dependant A 193 
deposition [2626]. Our results show that pomegranate significantly inhibited COX-2-194 
mediated PGE2 production in IL-1-stimulated SK-N-SH cells, suggesting that 195 
pomegranate could reduce the toxic effects of PGE2 overproduction in neurons.  196 
NF-κB plays a crucial role in regulating the transcription of a wide variety of genes 197 
and during neuroinflammation and neurodegeneration. In the cytoplasm NF-κB is 198 
coupled with IκB, an inhibitory protein which stays inactive. On activation, IB 199 
undergoes phosphorylation by IKK, resulting in the liberation of NF-κB. This free 200 
NF-κB translocates into the nucleus and binds to the promoter region of respective 201 
genes such as COX-2. Furthermore, NF-κB activation has been shown to control the 202 
transcription of the BACE-1 and APP genes in neurons [13]. To investigate the effect 203 
of pomegranate on NF-κB-mediated gene expression in general, a reporter gene 204 
assay was carried out. Results show that pomegranate significantly inhibited NF-κB-205 
driven luciferase expression in TNFα stimulated HEK293 cells, suggesting that this 206 
compound is able to attenuate NF-κB mediated gene expression. To gain a better 207 
understanding on the modulatory action of pomegranate on NF-κB signalling 208 
pathway we studied its activity on upstream protein targets. Results show that 209 
pomegranate blocked phosphorylation of IκB and IKK in SK-N-SH neuronal cells 210 
stimulated with IL-1; this outcome might suggest that pomegranate acts through 211 
interference with NF-κB pathway in neurons. These results were consistent with the 212 
outcome of studies conducted by Romier-Crouzet et al in human intestinal cells. 213 
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They reported that polyphenolic aqueous extract of pomegranate significantly 214 
suppressed NF-κB mediated NO, PGE2, IL-8 production in IL-1 activated Caco-2 215 
cells [27]. Our results also reflect the results of studies conducted by Ahmed et al 216 
where it was shown that pomegranate inhibited NF-κB in IL-1β-activated human 217 
chondrocytes [28]. 218 
In AD brains, A is generated through proteolysis of APP by -secretase enzymes. 219 
Several studies have identified BACE-1 as an important -secretase enzyme which 220 
effectively cleaves membrane bound APP [29]. In vivo studies in transgenic mice 221 
have also revealed that BACE-1 is highly involved in A plaque formation, and 222 
employing BACE-1 blockers has completely reversed A production [30]. As BACE-1 223 
transcription has been shown to be controlled by NF-κB [13], and since we have 224 
shown that pomegranate inhibits NF-κB signalling in SK-N-SH cells, we investigated 225 
whether pomegranate would block BACE-1 protein in IL-1-stimulated SK-N-SH 226 
cells. Expectedly, IL-1 induced marked increase in BACE-1 expression in these 227 
cells and this increase was significantly blocked with pomegranate pre-treatment. 228 
Interestingly, pomegranate also inhibited A protein induced by IL-1, suggesting 229 
that its effect is probably mediated through the observed interference with BACE-1 230 
enzymatic activity. 231 
These in vitro evidence of the potential nutritional benefits of pomegranate in AD 232 
does not prove bioavailability or in vivo biological activity of pomegranate 233 
polyphenols following oral intake in humans. However, bioavailability studies have 234 
shown that bioactive polyphenols in pomegranate are absorbed from the 235 
gastrointestinal tract. Lei et al. reported that punicalagin and ellagic acid reached a 236 
plasma concentration of 30 g/ml and 213 ng/ml, respectively following oral 237 
administration in rats [31]. A study in rabbits reported that pomegranate constituents 238 
become bioavailable 2 hours after oral ingestion of concentrated pomegranate 239 
extract, ellagic acid reaching a plasma value of 247 ng/ml [32]. In a human study, 240 
Seeram et al. administered 180 ml of pomegranate juice containing 25 mg ellagic 241 
acid and 318 mg ellagitanins to a human subject. Results of this study showed that 242 
ellagic acid was detected in human plasma at a concentration of 31.9 ng/ml 1 hour 243 
after ingestion [33]. Furthermore, ellagitannins in pomegranate have been shown to 244 
be metabolised by gut bacteria into urolithins that readily enter systemic circulation. 245 
These metabolites appeared in human systemic circulation within a few hours of 246 
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consumption of pomegranate products, reaching maximum concentrations between 247 
24 and 48 hours [34]. 248 
To provide benefits in CNS diseases like AD, pomegranate polyphenols must 249 
permeate the blood-brain barrier (BBB). It is not yet clear if biologically-active levels 250 
of these compounds could be detected in the CNS following oral administration. 251 
However, a study by Farbood et al [35] showed that oral administration of 100 mg/kg 252 
ellagic acid for seven days prevented cognitive and long-term potentiation deficits in 253 
rats. The outcome of this study suggests that ellagic acid permeated the BBB to act 254 
in the CNS. 255 
Our study did not establish if the concentrations of pomegranate used in the 256 
experiments contain quantities of ellagic acid and ellagitannins which reflect levels 257 
which have been detected in plasma. However, we can conclude that bioactive 258 
polyphenols in pomegranate could be absorbed from the gastrointestinal tract.  259 
In conclusion, we have provided further data showing that pomegranate inhibits 260 
induced inflammation in SK-N-SH cells. It appears that the effects of pomegranate 261 
on inflammatory processes in SK-N-SH cells results in a reduction of BACE-1 and 262 
the neurotoxic A. We propose that pomegranate is a potential nutritional strategy in 263 
slowing the progression of neuroinflammatory diseases such as AD, possibly 264 
through its anti-inflammatory effect. Further pharmacokinetic studies in animals and 265 
humans are needed to confirm whether pomegranate polyphenols permeate the 266 
BBB and reach biologically-active levels in the brain. 267 
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Figure legends 
Figure 1  
PWE reduced PGE2 production in IL-1-stimulated SK-N-SH cells. Cells were 
stimulated with IL-1 (10 U/ml) in the presence or absence of PWE (25-200 µg/ml) 
pre-incubated for 30 min. After 24 h, supernatants were collected for PGE2 
measurement. All values are expressed as mean±SEM for 3 independent 
experiments. Data were analysed using one-way ANOVA for multiple comparison 
with post-hoc Student Newman-Keuls test, *p < 0.05, **p<0.01, ***p<0.001 in 
comparison with IL-1 control. 
Figure 2 
PWE inhibited COX-2 protein expression in IL-1-stimulated SK-N-SH cells. Cells 
were stimulated with IL-1 (10 U/ml) in the presence or absence of PWE 
(25-200 µg/ml) pre-incubated for 30 min. After 24 h, COX-2 protein expression was 
determined using PathScan® sandwich ELISA. All values are expressed as 
mean±SEM for at least 3 independent experiments. Data were analysed using one-
way ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, *p < 
0.05, **p<0.01, ***p<0.001 in comparison with IL-1 control. 
Figure 3 
TNF-induced NF-κB-dependent gene expression in HEK293 cells was inhibited by 
PWE. Transfected cells were incubated with different concentrations of PWE 
followed by stimulation with TNF (1 ng/ml) for an additional 6 h. Luminescence was 
them measured. All values are expressed as mean±SEM for 3 independent 
experiments performed in triplicates. Data were analysed using one-way ANOVA for 
multiple comparison with post-hoc Student Newman-Keuls test, *p < 0.05, **p<0.01, 
***p<0.001 in comparison with TNF control. 
Figure 4 
PWE inhibited IL-1-induced IκB phosphorylation in SK-N-SH cells. Cells were 
stimulated with IL-1 (10 U/ml) in the presence or absence of PWE (25-200 µg/ml) 
pre-treated for 30 min. After 5 min, p-IκB protein expression was determined using 
PathScan® sandwich ELISA. All values are expressed as mean±SEM for 3 
independent experiments. Optical densities were measured at 450 nm with a micro 
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plate reader. Data were analysed using one-way ANOVA for multiple comparison 
with post-hoc Student Newman-Keuls test, *p < 0.05, **p<0.01, ***p<0.001 in 
comparison with IL-1 control. 
Figure 5 
PWE inhibited IL-1-induced IKK phosphorylation in SK-N-SH cells. Cells were 
stimulated with IL-1 (10 U/ml) in the presence or absence of PWE (25-200 µg/ml) 
for 5 min. At the end of incubation period, p-IKK protein expression was determined 
using PathScan® sandwich ELISA. All values are expressed as mean±SEM for 3 
independent experiments. Optical densities were measured at 450 nm with a micro 
plate reader. Data were analysed using one-way ANOVA for multiple comparison 
with post-hoc Student Newman-Keuls test, *p < 0.05, **p<0.01, ***p<0.001 in 
comparison with IL-1 control. 
Figure 6 
PWE inhibited IL-1-induced BACE-1 in SK-N-SH cells. Cells were pre-treated with 
PWE (25-200 µg/ml) 30 min before stimulation with IL-1 (10 U/ml) for 24 h. At the 
end of stimulation, levels of BACE-1 were determined using MaxDiscovery In Cell 
ELISA kit. All values are expressed as mean±SEM for 3 independent experiments. 
Optical densities were measured at 450 nm with a micro plate reader. Data were 
analysed using one-way ANOVA for multiple comparison with post-hoc Student 
Newman-Keuls test, *p < 0.05, **p<0.01, ***p<0.001 in comparison with IL-1 
control. GAPDH was used as internal control. 
Figure 7 
PWE attenuated IL-1-induced A production in SK-N-SH cells. Cells were pre-
treated with PWE (25-200 µg/ml) 30 min before stimulation with IL-1 (10 U/ml) for 
24 h. At the end of stimulation, A production was determined using MaxDiscovery 
In Cell ELISA kit. All values are expressed as mean±SEM for 3 independent 
experiments. Optical densities were measured at 450 nm with a micro plate reader. 
Data were analysed using one-way ANOVA for multiple comparison with post-hoc 
Student Newman-Keuls test, *p < 0.05, **p<0.01, ***p<0.001 in comparison with IL-
1 control. GAPDH was used as internal control. 
Figure 8 
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Pre-treatment with PWE (25-200 µg/ml) did not affect the viability of SK-N-SH cells 
stimulated with IL-1 (10 U/ml). Cells were per-incubated for 30 min with PWE (25-
200 µg/ml) in the presence or absence of IL-1 for 24 h. At the end of the incubation 
period, MTT and LDH assays were carried out on cells. All values are expressed as 
mean±SEM for 3 independent experiments. 
